The FDG-PET scan that initially revealed a mildly significant uptake of the radiopharmaceutical of the residual disease at three months from the end of radiotherapy, became totally negative after a further 3 months, confirming the effectiveness of our therapy choice.
← all excerpts
Castleman's disease in childhood: report of three cases and review of the literature.
1
—
—